Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P-IL-2 alone and with Anti-PD-1 in advanced solid tumors
NCT05829057Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- May 2023
- Primary completion
- Dec 2024
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of PEG-interleukin-2 in esophageal cancer, bladder cancer, liver cancer and 3 more (2 arms), sponsored by Zhejiang University. Primary endpoints: Dose Limiting Toxicity at 28 days, Adverse Events and Serious Adverse Events at 24 months and 1 more. Started May 2023; status: recruiting.
02
Drugs
PEG-interleukin-2
03
Conditions
esophageal cancerbladder cancerliver cancerovarian cancersmall cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05829057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05829057.